ODE Pharma is a pioneering biotechnology company at the forefront of developing innovative treatments for respiratory and pulmonary disorders. By harnessing the power of the body’s natural systems, specifically the gut microbiome and mitochondria, the company is driving advancements in healthcare and improving patient outcomes. ODE Pharma is currently developing ODE-001 that potentially enables cell restoration and regeneration, strengthens cells and reduces inflammation. ODE-001 has the potential to be indicated for the treatment of multiple respiratory and gastrointestinal diseases. By providing a required biochemical component to the cells’ powerhouses, and augmenting regulatory programs, ODE-001 renews and allows organs to survive longer and pass the organs’ failure breaking point.